At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
Memorial Sloan Kettering offers language assistance services for those who prefer to receive health information in another language. Learn more about our language assistance program here.
-
In people born with certain genetic mutations or whose tumors have these mutations, the standard treatment for breast cancer with CDK4/6 inhibitors (like palbociclib, ribociclib, or abemaciclib) might not be as effective. However, their tumors may still respond to a different type of drug called PARP inhibitors.
-
Researchers want to see if combining radiation therapy and immunotherapy is safe and works well for treating advanced adrenocortical cancer. The people in this study have adrenocortical cancer that spread to other parts of the body, including the liver.
-
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
-
The purpose of this study is to find the highest dose of the investigational drug NVL-520 that can be given safely in people with metastatic solid tumors that contain a change (fusion) involving the ROS1 gene. A fusion gene is made when parts of two different genes join together. NVL-520 blocks the ROS1 protein, which promotes cancer cell growth and survival. It is taken orally (by mouth
-
The purpose of this study is to find the highest doses of ruxolitinib and duvelisib when given together in patients with T-cell or NK-cell lymphoma that has come back or continued to grow despite prior treatment. The Food and Drug Administration (FDA) has approved ruxolitinib as a treatment for myelofibrosis and polycythemia vera (other blood disorders). The FDA has approved duvelisib to treat follicular lymphoma, small lymphocytic lymphoma, and chronic lymphocytic leukemia. The use of these two drugs together in this study is considered investigational.
-
Cells that are "mismatch repair-deficient" (MMR-D) or "microsatellite instability-high" (MSI-H) are unable to repair mistakes made during cell growth. Women with MMR-D/MSI-H endometrial cancer tend not to respond well to the chemotherapy they receive after surgery. Researchers are exploring the use of the immunotherapy TSR-042 (also called dostarlimab) as an alternative to chemotherapy. Radiation therapy is also used after surgery for endometrial cancer.
-
Researchers want to find the best doses of abemaciclib and cabozantinib to use in people with advanced kidney cancer. The people in this study have clear cell renal cell carcinoma that metastasized (spread); they previously received other kidney cancer therapies. In addition, their cancer keeps growing even after 2 or 3 prior treatments, including checkpoint inhibitor immunotherapy.
-
The purpose of this study is to see how well avutometinib and defactinib work in people with thyroid cancer. The people in this study have one of these kinds of cancer:
-
Researchers want to see how well quizartinib works to treat acute myeloid leukemia (AML). The people in this study have AML that does not have a genetic change called FLT3-ITD. In addition, they have not yet had any treatment for AML.
- A Phase 1 Study of DAY301 in People With Advanced Solid Tumors
Full Title A Phase 1, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of the PTK7-Targeted Antibody-drug Conjugate DAY301 in Patients with Locally Advanced or Metastatic Solid Tumors
Purpose
Researchers want to find the best dose of DAY301 to give to people with advanced solid tumors. The people in this study have solid tumors that have spread beyond their original location, including:
-
Head and neck cancer
-
Cancers of the esophagus, stomach, and gastroesophageal junction
- Non-small cell lung cancer and small cell lung cancer
- Gynecologic cancers: ovarian, endometrial, and cervical
-
Triple-negative breast cancer
DAY301 is a type of drug called an antibody-drug conjugate (ADC). ADCs are substances made up of a monoclonal antibody (special protein) linked to a drug. The antibody binds to specific proteins on certain types of cells, including cancer cells. The linked drug enters these cells and kills them. With ADCs, there is a lower risk of harming normal cells, since they usually do not have the target protein.
DAY301 targets cells with a protein called PTK7, which plays a role in cancer growth. By destroying these cells, DAY301 may help slow or stop the growth of your cancer. It is given intravenously (by vein).
Who Can Join
To join this study, there are a few conditions. You must:
- Have one of the advanced solid tumors listed above, which has spread beyond its original location.
- Have completed prior anti-cancer therapy at least 4 weeks before getting DAY301.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Robert Maki’s office at 646-888-5059.
Protocol
25-112Phase
Phase I (phase 1)Investigator
Co-Investigators
Diseases
Locations
ClinicalTrials.gov ID
NCT06752681ClinicalTrials.gov
-